PE20161132A1 - Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol - Google Patents
Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosolInfo
- Publication number
- PE20161132A1 PE20161132A1 PE2016000969A PE2016000969A PE20161132A1 PE 20161132 A1 PE20161132 A1 PE 20161132A1 PE 2016000969 A PE2016000969 A PE 2016000969A PE 2016000969 A PE2016000969 A PE 2016000969A PE 20161132 A1 PE20161132 A1 PE 20161132A1
- Authority
- PE
- Peru
- Prior art keywords
- aerosol
- composition
- formoterol
- cosolvent
- stabilizer
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229960002848 formoterol Drugs 0.000 title abstract 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
- 239000011707 mineral Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 229920005549 butyl rubber Polymers 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 1
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
- B65D83/141—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant specially adapted for specific contents or propellants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
- B65D83/44—Valves specially adapted for the discharge of contents; Regulating devices
- B65D83/52—Metering valves; Metering devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M2039/226—Spindles or actuating means
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Mechanical Engineering (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Steroid Compounds (AREA)
Abstract
Se refiere a una composicion farmaceutica en solucion para aerosol para utilizar con un inhalador presurizado de dosis medida, que comprende: a) bromuro de glicopirronio con una dosificacion entre 5 y 26 ug por accionamiento; b) formoterol, o una sal del mismo o un solvato de dicha sal, con una dosificacion entre 1 y 25 ug por accionamiento; c) un propelente que consiste en un HFA; d) un cosolvente; y e) un acido mineral como estabilizante en una cantidad util. Dicha composicion esta contenida en un envase de aerosol provisto de una valvula dosificadora que tiene por lo menos una junta de caucho butilico. En un aspecto preferido, el acido mineral es acido clorhidrico 1M, en una cantidad entre 0,15 y 0,28 ug/ul como estabilizante; y el cosolvente es etanol. En otro aspecto, dicha composicion comprende opcionalmente uno o mas ingredientes farmaceuticamente activos, seleccionados entre beta2 agonistas; corticoesteroides para inhalacion (dipropionato de beclometasona, budesonida, propionato de fluticasona, triamcinolona, prednisona, entre otros); agentes antimuscarinicos, e inhibidores de fosfodiesterasa4. El almacenamiento de dicha composicion en envases de aerosol provistos de una valvula dosificadora como se ha senalado anteriormente, minimiza las cantidades de productos de degradacion (particularmente DP3) durante su vida de estante, aun por debajo del umbral de deteccion despues del almacenamiento en condiciones severas de temperatura y humedad
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13199783 | 2013-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161132A1 true PE20161132A1 (es) | 2016-11-02 |
Family
ID=49886776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000969A PE20161132A1 (es) | 2013-12-30 | 2014-12-23 | Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20150182459A1 (es) |
| EP (1) | EP3096737B1 (es) |
| JP (2) | JP6534397B2 (es) |
| KR (1) | KR101865131B1 (es) |
| CN (2) | CN105848642A (es) |
| AR (2) | AR098983A1 (es) |
| AU (1) | AU2014375300B2 (es) |
| BR (1) | BR112016014586A2 (es) |
| CA (1) | CA2935302C (es) |
| CL (1) | CL2016001652A1 (es) |
| CY (1) | CY1120205T1 (es) |
| DK (1) | DK3096737T3 (es) |
| EA (1) | EA033228B1 (es) |
| ES (1) | ES2666905T4 (es) |
| GE (1) | GEP20186870B (es) |
| HR (1) | HRP20180944T1 (es) |
| HU (1) | HUE039359T2 (es) |
| IL (1) | IL246502B (es) |
| LT (1) | LT3096737T (es) |
| MA (1) | MA39154A1 (es) |
| ME (1) | ME03076B (es) |
| MX (1) | MX368834B (es) |
| MY (1) | MY176191A (es) |
| NO (1) | NO3096737T3 (es) |
| PE (1) | PE20161132A1 (es) |
| PH (1) | PH12016501269B1 (es) |
| PL (1) | PL3096737T3 (es) |
| PT (1) | PT3096737T (es) |
| RS (1) | RS57269B1 (es) |
| SA (1) | SA516371428B1 (es) |
| SG (1) | SG11201605309UA (es) |
| SI (1) | SI3096737T1 (es) |
| TN (1) | TN2016000262A1 (es) |
| TR (1) | TR201809356T4 (es) |
| UA (1) | UA117846C2 (es) |
| WO (1) | WO2015101575A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101738712B1 (ko) * | 2009-12-23 | 2017-05-22 | 키에시 파르마슈티시 엣스. 피. 에이. | Ｃｏｐｄ용 조합요법 |
| PH12012501066A1 (en) | 2009-12-23 | 2016-03-02 | Chiesi Farm Spa | Combination therapy for copd |
| EP2515854B1 (en) | 2009-12-23 | 2014-03-19 | Chiesi Farmaceutici S.p.A. | Aerosol formualtion for COPD |
| PL3096737T3 (pl) * | 2013-12-30 | 2018-08-31 | Chiesi Farmaceutici S.P.A. | Stabilna kompozycja w postaci ciśnieniowego roztworu aerozolowego kombinacji bromku glikopironium i formoterolu |
| JP6563950B2 (ja) * | 2013-12-30 | 2019-08-21 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧エアゾール溶液組成物 |
| GB201520862D0 (en) * | 2015-11-25 | 2016-01-13 | Jagotec Ag | Pharmaceutical composition |
| WO2017108917A1 (en) * | 2015-12-22 | 2017-06-29 | Astrazeneca Ab | Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| ES2968453T3 (es) | 2016-09-19 | 2024-05-09 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende glicopirrolato |
| EP3860580A4 (en) * | 2018-10-01 | 2022-07-20 | Kindeva Drug Delivery L.P. | FORMULATION AND AEROSOL CARTRIDGES, INHALATORS AND THE LIKE CONTAINING THE FORMULATION |
| US20220362225A1 (en) * | 2019-07-12 | 2022-11-17 | Kindeva Drug Delivery L.P. | Aerosol formulation, canister, and inhaler containing the formulation, and method of use |
| WO2021033081A1 (en) * | 2019-08-16 | 2021-02-25 | Glenmark Pharmaceutical Limited | Stable aerosol composition for inhalation comprising glycopyrronium, formoterol and corticosteroid |
| CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
| MX2022004781A (es) | 2019-12-02 | 2022-05-16 | Chiesi Farm Spa | Lata de acero inoxidable para inhaladores dosificadores presurizados. |
| US20210205223A1 (en) * | 2020-01-04 | 2021-07-08 | Cai Gu Huang | Propellant-free formulation for inhalation |
| PE20221867A1 (es) * | 2020-01-28 | 2022-12-02 | Chiesi Farm Spa | Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada |
| GB2593970B (en) * | 2020-02-20 | 2024-09-04 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| BR112023001689A2 (pt) | 2020-07-31 | 2023-05-02 | Chemo Res S L | Terapia de combinação para administração por inalação |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| DZ3358A1 (fr) * | 2000-05-22 | 2001-11-29 | Chiesi Farma Spa | Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US20040126325A1 (en) * | 2002-03-12 | 2004-07-01 | David Lewis | Medicinal aerosol solution formulation products with improved chemical stability |
| GB0315791D0 (en) * | 2003-07-07 | 2003-08-13 | 3M Innovative Properties Co | Two component molded valve stems |
| JP5524442B2 (ja) * | 2004-02-06 | 2014-06-18 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| KR20070010159A (ko) | 2004-05-13 | 2007-01-22 | 키에시 파르마슈티시 엣스. 피. 에이. | 화학안정성이 향상된 약제 에어로졸 제제 생성물 |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2201934A1 (en) * | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
| CA2764867C (en) * | 2009-06-09 | 2016-05-17 | Elevation Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| PH12012501066A1 (en) * | 2009-12-23 | 2016-03-02 | Chiesi Farm Spa | Combination therapy for copd |
| EP2515854B1 (en) | 2009-12-23 | 2014-03-19 | Chiesi Farmaceutici S.p.A. | Aerosol formualtion for COPD |
| WO2011076840A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Aerosol formulation for copd |
| KR101738712B1 (ko) | 2009-12-23 | 2017-05-22 | 키에시 파르마슈티시 엣스. 피. 에이. | Ｃｏｐｄ용 조합요법 |
| BR112013029507A2 (pt) * | 2011-05-17 | 2019-09-24 | Pearl Therapeutics Inc | método para tratar uma doença ou um distúrbio |
| JP6563950B2 (ja) * | 2013-12-30 | 2019-08-21 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧エアゾール溶液組成物 |
| PL3096737T3 (pl) * | 2013-12-30 | 2018-08-31 | Chiesi Farmaceutici S.P.A. | Stabilna kompozycja w postaci ciśnieniowego roztworu aerozolowego kombinacji bromku glikopironium i formoterolu |
-
2014
- 2014-12-23 PL PL14827449T patent/PL3096737T3/pl unknown
- 2014-12-23 CN CN201480071531.8A patent/CN105848642A/zh active Pending
- 2014-12-23 TN TN2016000262A patent/TN2016000262A1/en unknown
- 2014-12-23 SG SG11201605309UA patent/SG11201605309UA/en unknown
- 2014-12-23 NO NO14827449A patent/NO3096737T3/no unknown
- 2014-12-23 KR KR1020167020696A patent/KR101865131B1/ko active Active
- 2014-12-23 EA EA201691127A patent/EA033228B1/ru unknown
- 2014-12-23 MY MYPI2016001208A patent/MY176191A/en unknown
- 2014-12-23 PE PE2016000969A patent/PE20161132A1/es unknown
- 2014-12-23 AU AU2014375300A patent/AU2014375300B2/en active Active
- 2014-12-23 MX MX2016008591A patent/MX368834B/es active IP Right Grant
- 2014-12-23 WO PCT/EP2014/079258 patent/WO2015101575A1/en not_active Ceased
- 2014-12-23 HU HUE14827449A patent/HUE039359T2/hu unknown
- 2014-12-23 ME MEP-2018-149A patent/ME03076B/me unknown
- 2014-12-23 EP EP14827449.1A patent/EP3096737B1/en active Active
- 2014-12-23 BR BR112016014586A patent/BR112016014586A2/pt not_active Application Discontinuation
- 2014-12-23 LT LTEP14827449.1T patent/LT3096737T/lt unknown
- 2014-12-23 GE GEAP201414192A patent/GEP20186870B/en unknown
- 2014-12-23 MA MA39154A patent/MA39154A1/fr unknown
- 2014-12-23 PT PT148274491T patent/PT3096737T/pt unknown
- 2014-12-23 SI SI201430734T patent/SI3096737T1/en unknown
- 2014-12-23 CA CA2935302A patent/CA2935302C/en active Active
- 2014-12-23 TR TR2018/09356T patent/TR201809356T4/tr unknown
- 2014-12-23 CN CN202110424305.5A patent/CN113143894A/zh active Pending
- 2014-12-23 ES ES14827449.1T patent/ES2666905T4/es active Active
- 2014-12-23 RS RS20180635A patent/RS57269B1/sr unknown
- 2014-12-23 DK DK14827449.1T patent/DK3096737T3/en active
- 2014-12-23 HR HRP20180944TT patent/HRP20180944T1/hr unknown
- 2014-12-23 JP JP2016561078A patent/JP6534397B2/ja active Active
- 2014-12-23 UA UAA201606911A patent/UA117846C2/uk unknown
- 2014-12-29 AR ARP140104939A patent/AR098983A1/es not_active Application Discontinuation
- 2014-12-30 US US14/585,366 patent/US20150182459A1/en not_active Abandoned
-
2016
- 2016-06-28 IL IL246502A patent/IL246502B/en active IP Right Grant
- 2016-06-28 PH PH12016501269A patent/PH12016501269B1/en unknown
- 2016-06-28 SA SA516371428A patent/SA516371428B1/ar unknown
- 2016-06-28 CL CL2016001652A patent/CL2016001652A1/es unknown
- 2016-06-29 US US15/196,253 patent/US10617669B2/en active Active
- 2016-12-15 US US15/379,924 patent/US10596149B2/en active Active
-
2018
- 2018-05-15 CY CY20181100498T patent/CY1120205T1/el unknown
-
2019
- 2019-03-20 JP JP2019053624A patent/JP6826145B2/ja active Active
-
2023
- 2023-08-17 AR ARP230102184A patent/AR130238A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161132A1 (es) | Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol | |
| PE20160997A1 (es) | Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol | |
| AR115897A2 (es) | Composición farmacéutica para enfermedad pulmonar obstructiva crónica (epoc), frasco de aerosol que lo comprende, y método para rellenarlo | |
| PE20070951A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| MX2021009476A (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| CL2012001668A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros. | |
| AR104209A1 (es) | Formulación y contenedores de aerosol, inhaladores y similares que contienen la formulación | |
| RU2012125966A (ru) | Комбинированное лечение хронического обструктивного заболевания легких | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| PE20181488A1 (es) | Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico | |
| GEP20227418B (en) | Combination therapy for copd | |
| AR085059A1 (es) | Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla | |
| RU2012125965A (ru) | Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания | |
| AR088273A1 (es) | Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida | |
| PE20070353A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
| AR054230A1 (es) | Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestrante | |
| AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
| TH171993A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| TH171992A (th) | องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล | |
| GEP20257784B (en) | Stainles steel can for pressurised metered dose inhalers | |
| AR085443A1 (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero | |
| AR109186A1 (es) | Procedimiento de estabilización de tamaño de partícula de bromuro de glicopirronio | |
| AR100619A1 (es) | COMPOSICIÓN FARMACÉUTICA QUE COMBINA INHIBIDORES DE FOSFOINOSÍTIDO 3-QUINASA d Y CORTICOESTEROIDES PARA EL TRATAMIENTO DE ENFERMEDADES CUTÁNEAS INMUNOAMPOLLOSAS |